Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $49.24 USD
Change Today 0.00 / 0.00%
Volume 0.0
As of 8:10 PM 05/21/15 All times are local (Market data is delayed by at least 15 minutes).

takeda pharmaceutical co ltd (TKPHF) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/5/15 - $54.62
52 Week Low
12/30/14 - $41.16
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

takeda pharmaceutical co ltd (TKPHF) Details

Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, marketing, sale, and import/export of pharmaceutical drugs worldwide. It provides products in various therapeutic areas, including cardiovascular and metabolic, respiratory and immunology, oncology, central nervous system, general medicine, vaccines, and consumer healthcare drugs and quasi-drugs. The company has strategic partnership with BioMotiv, LLC; and a collaboration agreement with Mersana Therapeutics Inc. and Queen Mary University of London. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Osaka, Japan.

Founded in 1781

takeda pharmaceutical co ltd (TKPHF) Top Compensated Officers

Chief Financial Officer, Senior Vice Presiden...
Total Annual Compensation: ¥387.0M
Chief Medical & Scientific Officer, Director ...
Total Annual Compensation: ¥332.0M
Managing Director of Special Missions and Dir...
Total Annual Compensation: ¥93.0M
Compensation as of Fiscal Year 2014.

takeda pharmaceutical co ltd (TKPHF) Key Developments

Takeda Announces Seasonal Influenza Vaccine Sales Agreement with Kaketsuken in Japan

Takeda Pharmaceutical Company Limited announced that it has entered into an agreement with the Chemo-Sero-Therapeutic Research Institute (Head Office: Kumamoto City, Kumamoto Prefecture; Kaketsuken) for distribution of Kaketsukens seasonal influenza vaccine (Influenza HA Vaccine KAKETSUKEN,) in Japan, beginning in the upcoming season, 2015-2016. Takeda will continue to distribute the seasonal influenza vaccine, Influenza HA Vaccine SEIKEN, manufactured by Denka Seiken. Seasonal influenza typically occurs from early winter through early spring. Although most people quickly recover, there is a risk of progression to pneumonia, bronchitis and life-threatening severe complications, particularly in elderly individuals. As vaccination can protect against influenza infection and suppress the severity of symptoms, the Preventive Vaccination Law in Japan stipulates that the elderly are to receive regular vaccination. Given the aging population in Japan, the demand for seasonal influenza vaccine is increasing.

Takeda Pharmaceutical Company Limited Presents at FT Asia Pharma Healthcare Summit, May-20-2015 09:10 AM

Takeda Pharmaceutical Company Limited Presents at FT Asia Pharma Healthcare Summit, May-20-2015 09:10 AM. Venue: InterContinental, 80 Middle Road, Singapore, Singapore. Speakers: Giles Platford, President of Emerging Markets Business Unit.

Takeda Pharmaceutical Company Limited Announces Dividend for the Fiscal Year Ended March 31, 2015, Payable on June 29, 2015; Provides Dividend Guidance for the First Half 2016 and Fiscal Year Ending March 31, 2016

Takeda Pharmaceutical Company Limited announced a year end dividend of JPY 90.00 per share for the fiscal year ended March 31, 2015. The scheduled date of dividend payment commencement will be on June 29, 2015. For the end of first half 2016, the company expects to pay a dividend of JPY 90.00 per share. For the fiscal year ending March 31, 2016, the company expects to pay a dividend of JPY 90.00 per share.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
TKPHF:US $49.24 USD 0.00

TKPHF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $49.03 USD -0.31
Baxter International Inc $67.37 USD -0.17
Becton Dickinson and Co $141.94 USD -0.47
Biogen Inc $398.68 USD -2.47
Merck KGaA €101.23 EUR -0.229
View Industry Companies

Industry Analysis


Industry Average

Valuation TKPHF Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.6x
Price/Book 2.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TAKEDA PHARMACEUTICAL CO LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at